Mylan and Biocon Biologics Announce Launch of Semglee(TM) (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes

Semglee available in vial and pen presentations at a 65% discounted list price, the lowest available for a long-acting insulin glargine on the market HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Aug. 31, 2020 -- (Healthcare Sales & Market... Biopharmaceuticals, Generics, Product Launch Mylan, Biocon Ltd, Biocon Biologics India, Semglee, diabetes, insulin glargine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news